# Google Notes — Aligned with Latest Contents (Public Info Curation)

**Source:** Google Doc — [Public info curation - group 6 Rare disease](https://docs.google.com/document/d/1IplYThZIHmhCy0a8tcycNCAmia80iBRFTGT8La2ZUoU/edit)  
**Aligned with:** `google_doc_content.txt`, `summary2Feb.md` (15 tabs), `moreDocs.md`  
**Project focus:** How Hong Kong can work with Mainland China to enhance access to medicine for rare disease.

---

## 1. Summary of Google Doc tabs (from summary2Feb.md)

| Tab | Theme | Key point |
|-----|--------|-----------|
| 1 | Carrie Lam / SMA drug (2017) | CE promised nusinersen access; manufacturer had no HK plans; gaps in drug registration |
| 2 | Spare equipment (2012) | Families of SMA Trust; cough-assist machines; charity fills critical gap |
| 3 | Marcus Ng (2021) | 10yo SMA, 10% lung function; high-risk spinal surgery |
| 4–4b | LCQ16 rare diseases (Jun 2024) | HA databases 35→207; CCF subsidies; age limit 25 for SMA; no HA procurement from Mainland |
| 5 | HKCH SMA PDF | Patient info; types 1–4; early treatment best |
| 6 | Carmen Yau | SMA, disability and sex-rights advocate |
| 7 | Drug trial hope | Nusinersen trial HK; no effective therapy at time |
| 8 | Marcus Ng surgery | 8-hour spinal surgery; cost and access context |
| 9–10 | LCQ replies (Jun 2024) | SMA subsidy figures; age limit; "1+" mechanism |
| 11 | Review doc | Age limit, high cost, reactive policy, charity reliance, data gaps |
| 12 | "1+" extended (Oct 2024) | All new drugs from 1 Nov 2024 |
| 13 | Policy Address 2025 | GBA trials, Centre for Medical Products Regulation, innovative drugs office |
| 14–15 | HKCH SMA web; LCQ16 index | Same as above |

---

## 2. Past contents (google_doc_content.txt) — core four

1. **Carrie Lam / nusinersen** — CE promised to help SMA patients; manufacturer not introducing drug in HK; FHB to negotiate; compassionate arrangements.
2. **Spare machines** — SMA families rely on Families of SMA Trust for life-sustaining equipment; not readily available for quick purchase.
3. **Marcus Ng** — 10yo, SMA, high-risk spinal surgery to correct scoliosis and breathing.
4. **Gov reply Jun 2024** — LCQ reply: CCF subsidy for Nusinersen (80 applications, HK$183.54m) and Risdiplam (47, HK$74.19m); no subsidy for adults over 25; limited evidence cited.

---

## 3. Additional sources (moreDocs.md) — not in original 15 tabs

- **LCQ5** (Sep 2025): Rare disease relapses; HA database 207 entities; Mainland national lists.
- **LCQ22** (Oct 2025): Drug provision; transparency; reference Mainland price lists suggested.
- **"1+"** (Nov 2025): First advanced therapy product approved; 11 drugs by Feb 2025.
- **LCQ21** (Oct 2025): Achondroplasia treatment and support.
- **SCMP:** HK patients flocking to Mainland for faster, cheaper care; drug price cut (NHSA Nusinersen 700k→33k yuan); “road to treatment is slow”; opinion on outsourcing healthcare.
- **Straits Times:** Up to 10 times cheaper; HKU-Shenzhen 40,000+ HK outpatients Q1 2024.
- **HK–Shenzhen:** Research centre for real-world data to fast-track Mainland approval (Lo Chung-mau, Jun 2024).

---

## 4. Key themes for report (aligned with project focus)

- **HK–Mainland:** Government does *not* encourage HA to procure from Mainland (LCQ16); patients already buy from Mainland at ~5% of HK prices; GBA cooperation on trials/data, not procurement.
- **SMA:** Age limit 25 for subsidy; CCF figures; Mainland no age limit; NHSA negotiated large Nusinersen price cut.
- **"1+":** Speeds registration; does not address procurement or pricing from Mainland.
- **Recommendation direction:** Joint procurement or reference pricing with Mainland; review SMA age limit; better guidance for patients obtaining drugs from Mainland; transparency on drug prices.

---

## 5. Unique URLs (quick reference)

See `summary2Feb.md` § “Quick reference – unique URLs” for the full list. Key gov.hk links: LCQ16 (Jun 2024), LCQ21 SMA (Jun 2024), "1+" extension (Oct 2024), Policy Address 2025, LCQ5 (Sep 2025), LCQ22 (Oct 2025).

---

*Last aligned: 12 Feb 2026. Update this file when the Google Doc is updated and re-exported.*
